Successful Eisenmenger Syndrome‐targeted Drug Therapy in Pregnant Women: a Case Series and Literature Review

W. Chen,J. Chen,M. Peng,J. Luo,Y. Chen,H. Qiu,J. Li
DOI: https://doi.org/10.1111/1471-0528.17427
2023-01-01
Abstract:OBJECTIVE:To clarify the real-world outcomes in pregnant women with Eisenmenger syndrome (ES) in the new therapeutic era and provide a literature review.DESIGN:Retrospective case and literature review.SETTING:Tertiary referral hospital (The Second Xiangya Hospital of Central South University).SAMPLE:Thirteen women with ES delivered between 2011 and 2021.METHODS:Respective study and literature reviews.MAIN OUTCOMES MEASURES:Maternal and neonatal mortality and morbidity.RESULTS:12/13 (92%) pregnant women were treated with targeted drugs. 9/13 (69%) of patients had heart failure, but no maternal deaths occurred. 12/13 (92%) of women chose caesarean delivery. One pregnant woman gave birth at 37+1  weeks, and the remaining 12 (92%) patients had preterm birth. 10/13 (77%) women gave birth to live infants, of which 9/10 (90%) were low birthweight infants with a mean birthweight of 1575 g. The infant mortality rate was 1/10 (10%). Cardiac functional class improved during pregnancy, probably due to therapy; 11/13 (85%) of the pregnant women were in cardiac functional level III/IV at admission and 12 (92%) were in cardiac functional class II/III at discharge. Our literature review identified 72 cases of pregnancy with ES from 11 studies, which were characterised by a low rate of targeted drug use (28%) and a high maternal mortality rate of 24% in the perinatal period.CONCLUSION:Our case series and literature review suggest that targeted drugs may be key to improving maternal mortality in ES.
What problem does this paper attempt to address?